Liminatus Pharma Inc. (LIMN) vs NuCana PLC Sponsored ADR (NCNA)

Liminatus Pharma Inc. and NuCana PLC Sponsored ADR are both Biotechnology companies. Liminatus Pharma Inc. and NuCana PLC Sponsored ADR are of similar size ($5.7M and $5.6M). Across the 10 metrics below, Liminatus Pharma Inc. leads on 5 and NuCana PLC Sponsored ADR on 5.

Valuation

Metric LIMN NCNA Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 13.53 0.00 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 1.45 0.74
EV/Sales n/m n/m 10.73
Earnings yield (559.52%) (175,037.66%) (28.84%)
Free cash flow yield (97.71%) (131,687.13%) (23.03%)

Profitability

Metric LIMN NCNA Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 294.43% (68.70%) (57.72%)
Return on assets (471.47%) (45.24%) (49.22%)
Return on invested capital 0.00% (1,130.23%) 0.00%

Growth

Metric LIMN NCNA Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (112.19%) 98.96% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LIMN NCNA Biotechnology median
Debt to equity 4.80 0.00 0.00
Current ratio 1.12 4.73 4.73
Net debt to EBITDA (0.37) 1.23 0.96

Dividend

Metric LIMN NCNA Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric LIMN NCNA Biotechnology median
Market cap 5.61m 5.69m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack